Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)

被引：0
|
作者：
Kate McKeage
Barbara Romanowski
机构：
[1] Adis,Division of Infectious Diseases
[2] a Wolters Kluwer Business,undefined
[3] University of Alberta,undefined
来源：
BioDrugs | 2011年 / 25卷
关键词：
Cervical Intraepithelial Neoplasia; Sexual Debut; Cervarix; Premalignant Cervical Lesion; Aluminum Hydroxyphosphate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The AS04-adjuvanted human papillomavirus (HPV) 16/18 vaccine (Cervarix®) is a noninfectious recombinant vaccine produced using purified virus-like particles (VLPs) that induce a strong immunogenic response eliciting high levels of anti-L1 VLP antibodies that persist at levels markedly greater than those observed with natural infection. The vaccine adjuvant (AS04) is composed of monophosphoryl-lipid A, which enhances cellular and humoral immune response, adsorbed to aluminum hydroxide. The vaccine is indicated for the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types in females aged ≥10 years.
引用
收藏
页码：265 / 269
页数：4
相关论文
共 50 条
12345